

Fleur M Ferguson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9140147/publications.pdf>

Version: 2024-02-01

30
papers

1,960
citations

567144

15
h-index

454834

30
g-index

35
all docs

35
docs citations

35
times ranked

3709
citing authors

#	ARTICLE	IF	CITATIONS
1	Kinase inhibitors: the road ahead. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 353-377.	21.5	679
2	Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. <i>ELife</i> , 2019, 8, .	2.8	184
3	Mapping the Degradable Kinome Provides a Resource for Expedited Degradation Development. <i>Cell</i> , 2020, 183, 1714-1731.e10.	13.5	163
4	Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. <i>Nature Communications</i> , 2020, 11, 4687.	5.8	129
5	A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. <i>Science</i> , 2014, 346, 638-641.	6.0	128
6	Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 10183-10187.	2.9	92
7	Selective Mediator dependence of cell-type-specifying transcription. <i>Nature Genetics</i> , 2020, 52, 719-727.	9.4	84
8	Discovery of a selective inhibitor of doublecortin like kinase 1. <i>Nature Chemical Biology</i> , 2020, 16, 635-643.	3.9	84
9	Molecular Basis of Histone Tail Recognition by Human TIP5 PHD Finger and Bromodomain of the Chromatin Remodeling Complex NoRC. <i>Structure</i> , 2015, 23, 80-92.	1.6	59
10	TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. <i>Cancer Cell</i> , 2021, 39, 1262-1278.e7.	7.7	49
11	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazepinones as Inhibitors of Kinases and Bromodomains. <i>ACS Chemical Biology</i> , 2018, 13, 2438-2448.	1.6	44
12	Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. <i>Cell Chemical Biology</i> , 2020, 27, 525-537.e6.	2.5	36
13	Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113481.	2.6	27
14	Binding Hotspots of BAZ2B Bromodomain: Histone Interaction Revealed by Solution NMR Driven Docking. <i>Biochemistry</i> , 2014, 53, 6706-6716.	1.2	23
15	Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. <i>Cell Chemical Biology</i> , 2019, 26, 804-817.e12.	2.5	19
16	Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. <i>Cell Chemical Biology</i> , 2020, 27, 1229-1240.e4.	2.5	19
17	Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4880-4895.	2.9	17
18	Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzopyrimido[5,4-b][1,4]diazepin-6-one Scaffold. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7817-7826.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Discovery of a Series of 5,11-Dihydro-6H-benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-6-ones as Selective PI3K- β Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 908-912.	1.3	15
20	Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. <i>Proteomics</i> , 2021, 21, e2000098.	1.3	15
21	Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 346-352.	1.3	14
22	Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy. <i>Frontiers in Cellular Neuroscience</i> , 2022, 16, 801179.	1.8	14
23	Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1443-1449.	1.3	11
24	Characterization of a highly selective inhibitor of the Aurora kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4405-4408.	1.0	10
25	Targeted protein degradation: Emerging concepts and protein state-specific targeting principles. <i>Current Opinion in Chemical Biology</i> , 2022, 67, 102114.	2.8	7
26	Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1985-1993.	1.0	5
27	Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9. <i>Current Research in Chemical Biology</i> , 2021, 1, 100008.	1.4	3
28	Tuned out. <i>Nature Chemical Biology</i> , 2022, 18, 917-918.	3.9	3
29	Harnessing Antibody-Mimetic Selectivity for Activation-State-Specific Targeted Degradation of Endogenous K-Ras. <i>ACS Central Science</i> , 2021, 7, 222-224.	5.3	2
30	Assembling a Robust Workflow for Characterizing Endogenous E3 Ligase Substrates. <i>Biochemistry</i> , 2021, 60, 2365-2366.	1.2	0